Generated Narrative: CodeSystem protein-modification-type

This case-sensitive code system http://hl7.org/fhir/protein-modification-type defines the following codes:

Code Display Definition
PEGylated PEGylated Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol.
lipidated Lipidated Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec.
Fc-fused Fc fusion Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide.
albumin-fused Albumin fusion Fused to human serum albumin for half-life extension. Example: albiglutide.
drug-conjugated Drug-conjugated (ADC) Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin.
polysaccharide-conjugated Polysaccharide-conjugated Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines.
glycoengineered Glycoengineered Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC).
amino-acid-substituted Amino acid substituted Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine.
truncated Truncated Sequence is shortened relative to the parent protein.
biotinylated Biotinylated Covalently labelled with biotin. Typical for research or diagnostic reagents.
fluorescent-labeled Fluorescent labelled Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents.
<status value="active"/> <experimental value="true"/> <date value="2026-06-30"/> <publisher value="HL7 (FHIR Project)"/> <contact> <telecom> <system value="url"/> <value value="http://hl7.org/fhir"/> </telecom> <telecom> <system value="email"/> <value value="fhir@lists.hl7.org"/> </telecom> </contact> <description value="A high-level summary of how a protein has been modified, e.g. PEGylation, lipidation, Fc fusion. Useful for categorising modified biologics without enumerating the detailed chemistry."/> <jurisdiction> <coding> <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/> <code value="001"/> <display value="World"/> </coding> </jurisdiction> <caseSensitive value="true"/> <valueSet value="http://hl7.org/fhir/ValueSet/protein-modification-type"/> <content value="complete"/> <concept> <code value="PEGylated"/> <display value="PEGylated"/> <definition value="Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol."/> </concept> <concept> <code value="lipidated"/> <display value="Lipidated"/> <definition value="Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec."/> </concept> <concept> <code value="Fc-fused"/> <display value="Fc fusion"/> <definition value="Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide."/> </concept> <concept> <code value="albumin-fused"/> <display value="Albumin fusion"/> <definition value="Fused to human serum albumin for half-life extension. Example: albiglutide."/> </concept> <concept> <code value="drug-conjugated"/> <display value="Drug-conjugated (ADC)"/> <definition value="Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin."/> </concept> <concept> <code value="polysaccharide-conjugated"/> <display value="Polysaccharide-conjugated"/> <definition value="Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines."/> </concept> <concept> <code value="glycoengineered"/> <display value="Glycoengineered"/> <definition value="Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC)."/> </concept> <concept> <code value="amino-acid-substituted"/> <display value="Amino acid substituted"/> <definition value="Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine."/> </concept> <concept> <code value="truncated"/> <display value="Truncated"/> <definition value="Sequence is shortened relative to the parent protein."/> </concept> <concept> <code value="biotinylated"/> <display value="Biotinylated"/> <definition value="Covalently labelled with biotin. Typical for research or diagnostic reagents."/> </concept> <concept> <code value="fluorescent-labeled"/> <display value="Fluorescent labelled"/> <definition value="Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents."/> </concept> </CodeSystem>